Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The Gradual Release of Alendronate for the Treatment of Critical Bone Defects in Osteoporotic and Control Rats

V. Hedvičáková, R. Žižková, M. Buzgo, L. Vištejnová, P. Klein, M. Hovořáková, M. Bartoš, K. Steklíková, J. Luňáčková, E. Šebová, I. Paurová, M. Rysová, E. Filová, M. Rampichová

. 2023 ; 18 (-) : 541-560. [pub] 20230201

Language English Country New Zealand

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23004280

PURPOSE: Osteoporosis is a severe health problem with social and economic impacts on society. The standard treatment consists of the systemic administration of drugs such as bisphosphonates, with alendronate (ALN) being one of the most common. Nevertheless, complications of systemic administration occur with this drug. Therefore, it is necessary to develop new strategies, such as local administration. METHODS: In this study, emulsion/dispersion scaffolds based on W/O emulsion of PCL and PF68 with ALN, containing hydroxyapatite (HA) nanoparticles as the dispersion phase were prepared using electrospinning. Scaffolds with different release kinetics were tested in vitro on the co-cultures of osteoblasts and osteoclast-like cells, isolated from adult osteoporotic and control rats. Cell viability, proliferation, ALP, TRAP and CA II activity were examined. A scaffold with a gradual release of ALN was tested in vivo in the bone defects of osteoporotic and control rats. RESULTS: The release kinetics were dependent on the scaffold composition and the used system of the poloxamers. The ALN was released from the scaffolds for more than 22 days. The behavior of cells cultured in vitro on scaffolds with different release kinetics was comparable. The difference was evident between cell co-cultures isolated from osteoporotic and control animals. The PCL/HA scaffold show slow degradation in vivo and residual scaffold limited new bone formation inside the defects. Nevertheless, the released ALN supported bone formation in the areas surrounding the residual scaffold. Interestingly, a positive effect of systemic administration of ALN was not proved. CONCLUSION: The prepared scaffolds enabled tunable control release of ALN. The effect of ALN was proved in vitro and in in vivo study supported peri-implant bone formation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004280
003      
CZ-PrNML
005      
20230425141246.0
007      
ta
008      
230418s2023 nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/IJN.S386784 $2 doi
035    __
$a (PubMed)36756052
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Hedvičáková, Věra $u Department of Tissue Engineering, Institute of Experimental Medicine, the Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000302273347
245    14
$a The Gradual Release of Alendronate for the Treatment of Critical Bone Defects in Osteoporotic and Control Rats / $c V. Hedvičáková, R. Žižková, M. Buzgo, L. Vištejnová, P. Klein, M. Hovořáková, M. Bartoš, K. Steklíková, J. Luňáčková, E. Šebová, I. Paurová, M. Rysová, E. Filová, M. Rampichová
520    9_
$a PURPOSE: Osteoporosis is a severe health problem with social and economic impacts on society. The standard treatment consists of the systemic administration of drugs such as bisphosphonates, with alendronate (ALN) being one of the most common. Nevertheless, complications of systemic administration occur with this drug. Therefore, it is necessary to develop new strategies, such as local administration. METHODS: In this study, emulsion/dispersion scaffolds based on W/O emulsion of PCL and PF68 with ALN, containing hydroxyapatite (HA) nanoparticles as the dispersion phase were prepared using electrospinning. Scaffolds with different release kinetics were tested in vitro on the co-cultures of osteoblasts and osteoclast-like cells, isolated from adult osteoporotic and control rats. Cell viability, proliferation, ALP, TRAP and CA II activity were examined. A scaffold with a gradual release of ALN was tested in vivo in the bone defects of osteoporotic and control rats. RESULTS: The release kinetics were dependent on the scaffold composition and the used system of the poloxamers. The ALN was released from the scaffolds for more than 22 days. The behavior of cells cultured in vitro on scaffolds with different release kinetics was comparable. The difference was evident between cell co-cultures isolated from osteoporotic and control animals. The PCL/HA scaffold show slow degradation in vivo and residual scaffold limited new bone formation inside the defects. Nevertheless, the released ALN supported bone formation in the areas surrounding the residual scaffold. Interestingly, a positive effect of systemic administration of ALN was not proved. CONCLUSION: The prepared scaffolds enabled tunable control release of ALN. The effect of ALN was proved in vitro and in in vivo study supported peri-implant bone formation.
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a zvířata $7 D000818
650    12
$a alendronát $x farmakologie $7 D019386
650    _2
$a emulze $x farmakologie $7 D004655
650    _2
$a osteogeneze $7 D010012
650    _2
$a osteoklasty $7 D010010
650    _2
$a osteoblasty $7 D010006
650    _2
$a hydroxyapatit $x farmakologie $7 D017886
650    12
$a inhibitory kostní resorpce $x farmakologie $7 D050071
655    _2
$a časopisecké články $7 D016428
700    1_
$a Žižková, Radmila $u Department of Tissue Engineering, Institute of Experimental Medicine, the Czech Academy of Sciences, Prague, Czech Republic $u Department of Chemistry, Faculty of Science, Humanities and Education, Technical University of Liberec, Liberec, Czech Republic
700    1_
$a Buzgo, Matěj $u Department of Tissue Engineering, Institute of Experimental Medicine, the Czech Academy of Sciences, Prague, Czech Republic $u BIOFABICS Lda, Porto, Portugal
700    1_
$a Vištejnová, Lucie $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Klein, Pavel $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Department of Pathological Physiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Hovořáková, Maria $u Institute of Histology and Embryology, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000263466671 $7 xx0280695
700    1_
$a Bartoš, Martin $u Institute of Dental Medicine, First Faculty of Medicine and General University Hospital, Prague, Czech Republic $u Institute of Anatomy, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Steklíková, Klára $u Institute of Histology and Embryology, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000162212541
700    1_
$a Luňáčková, Jitka $u Institute of Dental Medicine, First Faculty of Medicine and General University Hospital, Prague, Czech Republic $1 https://orcid.org/000000025825368X
700    1_
$a Šebová, Eva $u Department of Tissue Engineering, Institute of Experimental Medicine, the Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000295928279
700    1_
$a Paurová, Iveta $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Rysová, Miroslava $u Department of Applied Biology, Institute for Nanomaterials, Advanced Technologies and Innovation, Technical University of Liberec, Liberec, Czech Republic $1 https://orcid.org/0000000333956941
700    1_
$a Filová, Eva $u Department of Tissue Engineering, Institute of Experimental Medicine, the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Rampichová, Michala $u Department of Tissue Engineering, Institute of Experimental Medicine, the Czech Academy of Sciences, Prague, Czech Republic
773    0_
$w MED00176143 $t International journal of nanomedicine $x 1178-2013 $g Roč. 18, č. - (2023), s. 541-560
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36756052 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141243 $b ABA008
999    __
$a ok $b bmc $g 1924760 $s 1190489
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 18 $c - $d 541-560 $e 20230201 $i 1178-2013 $m International journal of nanomedicine $n Int J Nanomedicine $x MED00176143
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options